Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689571 | 0.86 | MCL1 (0.53) | MCL1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL13986463 | 0.81 | SMN1; SMN2 (0.43) | KDM4EHSD17B10SMN1; SMN2CYP1A2POLB | |
| SCHEMBL3229944 | 0.78 | MCL1 (0.57) | MCL1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL7879847 | 0.78 | MCL1 (0.57) | MCL1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL10233030 | 0.78 | MCL1 (0.57) | MCL1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL13456549 | 0.76 | MCL1 (0.56) | MCL1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL5600801 | 0.76 | MCL1 (0.56) | MCL1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3258061 | 0.76 | MCL1 (0.56) | MCL1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL689437 | 0.76 | MCL1 (0.56) | MCL1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL18000310 | 0.76 | CMA1 (0.35) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786801-B1 | 2-ARYLCARBAMOYL-INDOLES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7470692-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470692-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470692-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1786801-A1 | CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006026235-A1 | CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060046986-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046986-A1 | Cytokine inhibitors | IL1B, TNF, IL1A | MCL1 1950/4885ALDH1A1 297/4885KDM4E 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.